Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings, Inc. (NASDAQ: ASRT) will announce its third quarter 2021 financial results on November 4, 2021, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time on the same day. Stakeholders can join the call using the provided dial-in numbers: 1 (844) 200-6205 for domestic and 1 (929) 526-1599 for international participants. Assertio is known for its differentiated pharmaceutical products in the fields of neurology, hospital, and pain and inflammation.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced investor presentations at several upcoming conferences. CEO Dan Peisert and CFO Paul Schwichtenberg will present at the LD Micro Main Event from October 12-14, 2021, the Stifel 2021 Virtual Healthcare Conference from November 15-17, and the Q4 Investor Summit from November 16-17. Additionally, they will participate in the Sidoti & Company Virtual Microcap Conference on December 8-9. Detailed information and live webcasts will be available on their investor website.
Assertio Holdings, Inc. reported net product sales of $24.8 million for Q2 2021, a significant increase from $20.2 million in Q2 2020. The company also raised its full year guidance for net product sales to $91-$96 million, up from $85-$92 million. Despite a net loss of $14.2 million in Q2, improved execution of cost-saving measures is expected to enhance adjusted EBITDA to between $34-$37 million. The company's transition to a non-personal promotional model has also contributed positively.
In addition, a legal reserve of $11.3 million was established, and the company regained compliance with NASDAQ after a reverse stock split.
Assertio Holdings (NASDAQ: ASRT) plans to release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call hosted by management will follow at 4:30 p.m. Eastern Time. Investors can access the live webcast and replay on the company's investor website. Assertio specializes in pharmaceutical products in neurology, hospital, and pain management. The company has achieved growth through licensing, mergers, and acquisitions.
Assertio Holdings, Inc. (ASRT) announced it has regained compliance with the Nasdaq's minimum bid price requirement, signaling a positive development for the company. The notification letter from Nasdaq confirms that the compliance issue is now resolved. Assertio continues to focus on its portfolio of branded prescription products in neurology, hospital, and pain management areas, driven by strategic growth through licensing and acquisitions.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced a one-to-four reverse stock split effective May 18, 2021. This means that every four shares will convert into one share, without altering the par value per share. Adjustments will also be made to stock options, warrants, and equity compensation plans. Fractional shares will be compensated based on the stock's closing price on May 17, 2021. The company will continue trading under the symbol ASRT.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced a partial adjournment of its 2021 Annual Meeting on May 11, 2021, primarily to gather additional votes for Proposals 2 and 3. Proposal 2, concerning a Reverse Split and Proportional Authorized Shares Reduction, has over 80% support from votes cast but requires approval from more than 50% of all outstanding shares. Proposal 3 also shows strong preliminary support of over 76%. Leading advisory firms recommend both proposals, aiming at compliance with Nasdaq listing requirements. The reconvened meeting is set for June 9, 2021.
Assertio Holdings, Inc. (ASRT) reported a net product sales of $26.4 million for Q1 2021, a decrease from $28.3 million pro forma sales in Q1 2020. The company's net income fell to $4.5 million from $41.2 million year-over-year. However, Adjusted EBITDA surged to $15.7 million compared to $3.9 million in the previous year. Assertio anticipates full-year 2021 net sales between $85.0 million and $92.0 million. The company has raised $45.3 million in cash to enhance liquidity and implemented a restructuring plan aiming for $45 million in annualized cost savings.
Assertio Holdings and Cove have partnered to enhance patient access to CAMBIA (diclofenac potassium) and SPRIX (ketorolac tromethamine) through Cove’s telemedicine platform. This collaboration aims to facilitate consultations with licensed physicians who can prescribe these medications for migraine treatment and pain management. The initiative aligns with Assertio's strategy for digital engagement and direct-to-patient care models, potentially expanding their reach in the market and improving patient convenience.
Assertio Holdings, Inc. (NASDAQ: ASRT) will announce its first quarter 2021 financial results on May 6, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results. Investors can access the live webcast at Assertio's investor relations website. Assertio is recognized for its differentiated pharmaceutical products in neurology, hospital, and pain management, having experienced growth through licensing and acquisitions.